Outcomes of Patients With CML Treated With Third-Line BCR-ABL1 TKIs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
American Journal of Hematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors
Am. J. Hematol 2023 Jan 22;[EPub Ahead of Print], EJ Jabbour, K Sasaki, FG Haddad, GC Issa, G Garcia-Manero, TM Kadia, N Jain, M Yilmaz, CD DiNardo, KP Patel, R Kanagal-Shamanna, R Champlin, IF Khouri, S Dellasala, SA Pierce, H KantarjianFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.